The Filing Desk

Ultragenyx Pharmaceutical

RARE · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

RARE · Last close · November 13, 2026
$16.08
Value Ultragenyx Pharmaceutical yourself

Ultragenyx Pharmaceutical's revenue rose 20.2% to $673 million in fiscal 2025. Its operating margin was −79.5%, up from −95.7% a year earlier. Free cash flow was −$472 million. The diluted share count rose 8.9%.

ULTRAGENYX PHARMACEUTICAL INC. Latest fiscal year ended December 31, 2025 10-K filed February 18, 2026 · 0001193125-26-057329 Updated
Revenue
$673M
20.2%
Operating margin
−79.5%
16.2 pts
Net income
−$575M
 
Free cash flow
−$472M
 
Return on equity
−657.1%
442.4 pts
Market cap
$1.6B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Ultragenyx Pharmaceutical does

Ultragenyx is a drug company that develops and sells treatments for rare and ultra-rare genetic diseases, many of which have no approved therapy that treats the underlying cause. It uses several kinds of medicine: biologics (made from living cells), small molecules, gene therapy that uses a harmless virus to deliver genes, and nucleic acid drugs.

It earns money from its approved products. They include Crysvita, an antibody for X-linked hypophosphatemia (a bone disease) and a related tumor-linked condition, which it develops and sells together with Kyowa Kirin, and Mepsevii, an enzyme therapy for a very rare disorder called MPS VII. It also has Evkeeza, an antibody for a rare inherited form of high cholesterol, which its partner Regeneron markets in the United States. The company mostly licenses its drug candidates from universities or other drug makers and aims to keep worldwide selling rights.

It has its own sales teams in North America, Europe, the United Kingdom, Latin America, Türkiye and Asia, and uses distributors in smaller markets. Alongside its sold products it runs a set of clinical-stage programs, which are medicines still being tested in people.

Its biggest risks, as it describes them

  • It depends on Kyowa Kirin for the development, supply and sale of Crysvita, one of its main products.
  • Its drug candidates can fail in later trials even after promising early results, or be delayed.
  • Regulators may not approve its candidates, or may approve them for narrower uses than it wants.
  • It has a limited operating history and may need to raise more money.
  • Making gene therapies and other complex medicines is difficult, and it relies on outside makers.
From Ultragenyx Pharmaceutical's annual report on Form 10-K, filed February 18, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Ultragenyx Pharmaceutical lost money in fiscal 2025: a net loss of $575 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments740748578610680
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio4.7x3.4x2.6x2.4x2.5x
Quick ratio4.6x3.3x2.5x2.2x2.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Ultragenyx Pharmaceutical's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Ultragenyx Pharmaceutical says to expect

  • Full year 2026: total revenueThe company reaffirms its full year 2026 total revenue guidance of $730 million to $760 million, which excludes revenue from new product launches.
  • Full year 2026: Crysvita revenueThe company reaffirms its full year 2026 Crysvita revenue guidance of $500 million to $520 million.
  • Full year 2026: Dojolvi revenueThe company reaffirms its full year 2026 Dojolvi revenue guidance of $100 million to $110 million.
  • Full year 2027: R&D and SG&A expensesTo support this transition, the company has initiated substantial headcount and expense reductions and expects to reduce 2027 R&D expenses to less than $350 million and 2027 SG&A expenses to less than $375 million.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 3, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Ultragenyx Pharmaceutical shares on the open market, and 9 insiders sold $3.7 million, $1.3 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 15, 2026Theodore Alan HuizengaSVP, Chief Accounting OfficerSold plan1,283$13.57$17,410Form 4
Sep 3, 2026Theodore Alan HuizengaSVP, Chief Accounting OfficerSold161$13.99$2,252Form 4
Aug 3, 2026Howard HornChief Financial OfficerSold plan4,696$24.92$117,024Form 4
Aug 3, 2026Karah Herdman ParschauerEVP and Chief Legal OfficerSold plan1,900$24.92$47,348Form 4
Jul 1, 2026Howard HornChief Financial OfficerSold plan4,698$33.13$155,645Form 4
Jun 15, 2026Corazon (Corsee) D. SandersDirectorSold2,000$25.05$50,100Form 4
Jun 15, 2026Karah Herdman ParschauerEVP and Chief Legal OfficerSold plan1,899$24.62$46,753Form 4
Jun 1, 2026Howard HornChief Financial OfficerSold plan4,653$23.77$110,602Form 4
May 18, 2026Shehnaaz SulimanDirectorSold plan5,740$25.12$144,189Form 4
May 5, 2026Eric CrombezEVP and Chief Medical OfficerSold344$24.96$8,586Form 4
May 1, 2026Howard HornChief Financial OfficerSold plan4,683$24.90$116,607Form 4
Apr 1, 2026Howard HornChief Financial OfficerSold plan4,683$20.97$98,203Form 4
The latest 12 of 26 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−100.1%−46.1%−50.0%
Altman Z''−7.75−8.70−9.61
Accruals ratio−8.7%−10.3%−7.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassPassFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Ultragenyx Pharmaceutical side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Ultragenyx PharmaceuticalFY2520.2%−79.5%−70.1%———
Kiniksa PharmaceuticalsFY2560.1%11.4%20.1%———Compare
Amphstar PharmaceuticalsFY25−1.6%19.5%16.8%9.9%1.7x6Compare
Pacira BioSciencesFY253.6%2.6%18.8%1.1%1.2x9Compare
OPKO HealthFY25−14.9%−19.4%−31.4%−7.0%—4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue0352104271351363434560673
Revenue growth—1,863.9%1,871.5%101.4%161.3%29.7%3.4%19.4%29.0%20.2%
Gross profit—350———————
Research and development183232294357412497706648698750
Operating income−248−329−371−424−330−382−649−569−536−535
Net income−246−302−198−403−187−454−707−607−569−575
Diluted EPS (US$)−6.21−7.12−3.97−7.12−3.07−6.70−10.12−8.25−6.29−5.83
Diluted shares (millions)40425057616870749099
Cash flow
Cash from operations−161−254−291−345−132−339−380−475−414−466
Capital expenditure10342544731164476
Free cash flow−171−257−295−370−176−412−497−519−421−472
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0143000075000
Stock-based compensation4868808286105130135158153
Balance sheet at fiscal year end
Cash and short-term investments3802344607551,202740748578610680
Debt incl. finance leases——————————
Total assets5414917201,1361,7601,5221,5451,4911,5031,532
Total liabilities671071114826056001,1931,2161,2411,605
Shareholders' equity4743846096541,154923352275255−80
Margins and ratios
Gross margin—100.0%97.8%———————
Operating margin−186,471.4%−12,593.5%−721.2%−409.0%−121.8%−108.6%−178.6%−131.1%−95.7%−79.5%
Net margin−184,867.7%−11,567.3%−383.8%−388.3%−68.8%−129.2%−194.7%−139.9%−101.6%−85.4%
Free cash flow margin−128,694.0%−9,825.3%−572.2%−357.0%−65.0%−117.2%−136.7%−119.6%−75.2%−70.1%
Rule of 40 (growth + FCF margin)—−7,961.4%1,299.3%−255.6%96.3%−87.5%−133.3%−100.1%−46.1%−50.0%
Return on capital——————————
Return on equity−48.9%−70.5%−39.8%−63.8%−20.6%−43.7%−111.0%−193.6%−214.7%−657.1%
Return on assets−44.7%−58.6%−32.6%−43.4%−12.9%−27.7%−46.1%−40.0%−38.0%−37.9%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Ultragenyx Pharmaceutical's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Ultragenyx Pharmaceutical.